The Latest Breaking News from 23andMe

23andMe's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control and benefits.

The president sold the US model of the industry that made it: enormous power concentrated in the hands of a few men

Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection

“I think one of the takeaways of the book is that success kind of is a moment in time,” says author Susan Dominus.

The Information Commissioner’s Office has said it will take action if it believe UK data protection law is not followed.

If there’s a disease that seems to run in your family, if you’ve had a negative reaction to a drug or wondered why a standard treatment didn’t work on you, the answers may lie in your genes.

After almost three decades in New Zealand, loyalty programme Flybuys announced it would be closing in 2024. The company behind the scheme, Loyalty New Zealand, has since entered liquidation, leaving the future of one of Flybuys’ key assets uncertain.

Republican Rep. James Comer is giving 23andMe a deadline to hand over documents and communications related to its bankruptcy filing as it seeks to determine what will happen to the genetic data of those who used the company's service

The bankruptcy of genealogy company 23andMe has resulted in a fire sale of millions of people’s genetic information – and there’s no shortage of eager buyers with questionable motives

As soon as the genetic testing company 23andMe filed for bankruptcy on March 23, 2025, concerns about what would happen to the personal information contained in its massive genetic and health information database were swift and widespread. A few days after, a U.S. judge ruled that the company could sell…